European journal of cancer : official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
-
Review Meta Analysis
Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis.
Fatal adverse events (FAEs) have been reported in cancer patients receiving ipilimumab-a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, but the risk of treatment-related mortality is unknown. We performed a systematic review and meta-analysis of randomised controlled trials (RCTs) of ipilimumab to determine the overall risk of FAEs associated with ipilimumab. ⋯ The use of ipilimumab, compared with controls, was associated with increased risk of treatment-related mortality.